'Deeply committed' Jim Wilson pours more of his life's work into Passage Bio — locking in more gene therapy programs, new tech
From Passage Bio’s inception last February to its IPO filing a year later, its close relationship with co-founder Jim Wilson’s Gene Therapy Program at the University of Pennsylvania has always been touted as a major strength. Now the biotech is tying an even tighter knot with its academic partner.
In a deal expansion, Passage nabbed the option to license five more programs coming out of Wilson’s lab and extended the exercise period by three years to 2025. If all the candidates end up making the cut, they will feed 17 new treatments for rare monogenic diseases all the way through clinical development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
